Related Experiment Video
Updated: Apr 20, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour
Ferdinando C M Cananzi1, Ajay Belgaumkar, Bruno Lorenzi
1Department of Surgery, The Royal Marsden, London, UK.
Background:
After the introduction of tyrosine kinase inhibitors (TKIs), the role of surgical resection in treating liver metastasis from gastrointestinal stromal tumour (GIST) is unclear. In this study, we evaluated the outcome of patients treated with TKIs followed by surgery for metastatic GIST.
Methods:
Eleven patients who underwent liver resection after downsizing TKIs therapy for metastatic GIST from 2006 until 2010 were reviewed.
Results:
One and 2-year overall survival (OS) rates were 80.8% and 70.7%. All patients with an initially resectable tumour were still alive without recurrence. Patients operated on clinical response had a better outcome (1-year and 2-year OS rate of 100%) than those operated on disease progression (1-year and 2-year OS rates of 60% and 40%; P = 0.043). No deaths were observed among patients who achieved an R0 resection (R0 versus R1/R2, P = 0.001).
Conclusion:
R0 resection and clinical response to TKI are predictors of survival. Surgical resection should be performed as soon as feasible in responder patients. In poor responders, surgery may not add any survival benefit, except in localized progressive disease. In resectable metastatic liver disease, preoperative TKIs or upfront surgery followed by adjuvant therapy could be considered. Larger studies are needed to determine the optimum approach in patients with metastatic GIST.
Insights
Surgical resection after tyrosine kinase inhibitors (TKIs) shows promise for metastatic gastrointestinal stromal tumour (GIST) liver metastasis. Achieving R0 resection and responding to TKIs are key predictors of improved survival in these patients.
Area of Science:
- Oncology
- Surgical Oncology
- Gastrointestinal Oncology
Background:
- The role of surgical resection for liver metastasis in gastrointestinal stromal tumour (GIST) is uncertain following the advent of tyrosine kinase inhibitors (TKIs).
- Evaluating outcomes for patients with metastatic GIST treated with TKIs followed by surgical resection is crucial.
Purpose of the Study:
- To assess the survival outcomes of patients with metastatic GIST who underwent liver resection after neoadjuvant TKI therapy.
- To identify predictors of survival in this patient cohort.
Main Methods:
- A retrospective review of eleven patients who underwent liver resection for metastatic GIST between 2006 and 2010 after TKI therapy.
- Analysis of overall survival (OS) rates, recurrence, and impact of resection margins (R0 vs. R1/R2) and clinical response to TKIs.
Main Results:
- One and 2-year OS rates were 80.8% and 70.7%, respectively.
- Patients achieving R0 resection had significantly better outcomes (no observed deaths) compared to R1/R2 resection (P=0.001).
- Clinical responders to TKIs demonstrated superior survival (1- and 2-year OS of 100%) compared to non-responders (P=0.043).
Conclusions:
- Complete (R0) resection and positive clinical response to TKIs are significant predictors of survival in metastatic GIST liver metastasis.
- Surgical resection should be considered early for TKI responders. For poor responders, surgery's benefit is limited, except in localized progressive disease.
- Further research is needed to establish the optimal treatment strategy for metastatic GIST, including neoadjuvant TKIs versus upfront surgery.
More Related Videos
05:16Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
Published on: February 19, 2022
04:22Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
Published on: March 3, 2023
